학술논문

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Document Type
Article
Source
In: Journal of Clinical Oncology. (Journal of Clinical Oncology, 1 April 2024, 42(10):1193-1201)
Subject
Language
English
ISSN
15277755
0732183X